Form 8-K - Current report:
SEC Accession No. 0001193125-25-147017
Filing Date
2025-06-25
Accepted
2025-06-25 16:45:18
Documents
18
Period of Report
2025-06-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d944948d8k.htm   iXBRL 8-K 36606
2 EX-1.1 d944948dex11.htm EX-1.1 240095
3 EX-4.1 d944948dex41.htm EX-4.1 69140
4 EX-5.1 d944948dex51.htm EX-5.1 15077
5 EX-99.1 d944948dex991.htm EX-99.1 8859
9 GRAPHIC g944948dsp77.jpg GRAPHIC 5719
10 GRAPHIC g944948g0624200618124.jpg GRAPHIC 5411
  Complete submission text file 0001193125-25-147017.txt   601449

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20250624.xsd EX-101.SCH 2860
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20250624_lab.xml EX-101.LAB 17995
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20250624_pre.xml EX-101.PRE 11268
20 EXTRACTED XBRL INSTANCE DOCUMENT d944948d8k_htm.xml XML 3629
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 251074147
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)